Security key
68062P106
Olema Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (OLMA)
CUSIP: 68062P106
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 1,198
- Total 13F value
- $14,987
- Share change
- -181
- SEC-reported price per share
- $12.51
- Number of holders
- 1
- Value change
- -$2,264
- Number of sells
- 1
- Shares outstanding
- 91,696,172
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
1
Top holders
1
OLMA full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Olema Pharmaceuticals, Inc. SEC filings
Olema Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 68062P106
Recent filing periods:
Ownership snapshot
Top reported holders of OLMA - Olema Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 12%
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 12%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
12%
Paradigm Biocapital Advisors LP
10%
JANUS HENDERSON GROUP PLC
8.2%
Bain Capital Life Sciences Opport...
8.2%
Invus Global Management, LLC
5.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
12%
|
$250,051,474
9,998,060 shares
|
+$124,423,925 | 27 Feb 2026 |
| Paradigm Biocapital Advisors LP |
3/4/5
13D/G
13F
10%+ Owner · Company
|
10%
from 13D/G
|
$173,767,954
13,407,200 shares
|
— | 01 Aug 2024 |
| JANUS HENDERSON GROUP PLC |
13F
13D/G
Company
|
8.2%
from 13D/G
|
$106,013,431
7,108,488 shares
|
— | 31 Mar 2026 |
| Bain Capital Life Sciences Opportunities IV, L.P. |
13D/G
|
8.2%
|
$111,425,979
7,473,238 shares
|
-$15,437,859 | 31 Mar 2026 |
| Invus Global Management, LLC |
13D/G
Raymond Debbane
|
5.1%
|
$108,693,078
4,461,949 shares
|
$0 | 16 Mar 2026 |
| Logos Global Management LP |
13F
13D/G
Company
|
4.7%
from 13D/G
|
$47,844,326
3,208,875 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
1,198
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
193
Q2 2026 holders
1
Holder diff
-192
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend